XML 11 R33.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Commitments and Contingencies (Details Textual) (USD $) | 3 Months Ended | 9 Months Ended |  |  | 0 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 0 Months Ended | 1 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | 9 Months Ended |  |  |  |  | 1 Months Ended | 9 Months Ended |  | 1 Months Ended |  | 9 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Jun. 20, 2014 | Dec. 31, 2013 | Jan. 27, 2014 Manufacturing Agreement [Member] | Sep. 30, 2014 Manufacturing Agreement [Member] | Sep. 30, 2014 Einstein [Member] | Sep. 30, 2014 Abbview Biotherapeutics Corp [Member] Product Development and Patent License Agreement [Member] | Sep. 30, 2014 Abbview Biotherapeutics Corp [Member] After First Net Sales [Member] | Sep. 30, 2014 Abbview Biotherapeutics Corp [Member] Phase I Clinical Trial of a licensed product [Member] | Sep. 30, 2014 Abbott Biotherapeutics Corp [Member] After First Net Sales [Member] Product Development and Patent License Agreement [Member] | Sep. 30, 2014 Abbott Biotherapeutics Corp [Member] Phase I Clinical Trial of a licensed product [Member] | Sep. 30, 2014 Oak Ridge National Laboratory [Member] 2013 [Member] | Sep. 30, 2014 Oak Ridge National Laboratory [Member] 2014 [Member] | May 16, 2013 Aptiv Solutions [Member] | Oct. 22, 2012 Aptiv Solutions [Member] | Aug. 06, 2012 Aptiv Solutions [Member] | Dec. 31, 2007 Aptiv Solutions [Member] | Sep. 30, 2014 Aptiv Solutions [Member] | Dec. 31, 2012 Aptiv Solutions [Member] | Jun. 15, 2012 Fred Hutchinson Cancer Research Center [Member] license and sponsored research agreement [Member] | Sep. 30, 2014 Fred Hutchinson Cancer Research Center [Member] license and sponsored research agreement [Member] | Sep. 30, 2013 Fred Hutchinson Cancer Research Center [Member] license and sponsored research agreement [Member] | Sep. 30, 2014 Fred Hutchinson Cancer Research Center [Member] Clinical Trial Agreement [Member] | Dec. 31, 2013 Fred Hutchinson Cancer Research Center [Member] Clinical Trial Agreement [Member] | Jul. 19, 2012 Fred Hutchinson Cancer Research Center [Member] Clinical Trial Agreement [Member] | Jun. 15, 2012 Fred Hutchinson Cancer Research Center [Member] Maximum [Member] license and sponsored research agreement [Member] | Jun. 15, 2012 Fred Hutchinson Cancer Research Center [Member] Minimum [Member] license and sponsored research agreement [Member] | Aug. 28, 2012 University of Texas M.D. Anderson Cancer Center [Member] Clinical Trial Agreement [Member] patients | Sep. 30, 2014 University of Texas M.D. Anderson Cancer Center [Member] Clinical Trial Agreement [Member] | Jul. 31, 2013 University of Texas M.D. Anderson Cancer Center [Member] Clinical Trial Agreement [Member] | Sep. 26, 2012 Johns Hopkins University [Member] Clinical Trial Agreement [Member] | Sep. 30, 2014 Johns Hopkins University [Member] Clinical Trial Agreement [Member] | Sep. 30, 2014 University of Pennsylvania [Member] Clinical Trial Agreement [Member] | Dec. 31, 2013 University of Pennsylvania [Member] Clinical Trial Agreement [Member] | Nov. 21, 2012 University of Pennsylvania [Member] Clinical Trial Agreement [Member]
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales in milestones payment |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License fee payment |  |  |  |  |  |  |  |  |  | 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones payments |  |  |  |  |  |  |  |  |  | 7,750,000 | 1,500,000 | 750,000 |  | 750,000 |  |  |  |  |  |  |  |  | 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of royalty payment |  |  |  |  |  |  |  |  |  | Company shall pay to AbbVie Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire. |  |  |  |  |  |  |  |  |  |  |  |  |  | Royalty payments of 2% of net sales will be due to FHCRC. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty of net sales percentage |  |  |  |  |  |  |  |  |  | 12.00% |  |  |  |  |  |  |  |  |  |  |  |  | 2.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
First commercial sale period |  |  |  |  |  |  |  |  |  | 12 years 6 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of radioactive material used for research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 300,000 | 400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Project estimated cost for clinical trials of drug Ac-225-HuM195 |  |  |  |  |  |  | 3,300,000 | 2,300,000 |  |  |  |  |  |  |  |  | 2,200,000 | 2,200,000 | 2,200,000 |  | 1,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Down payment of project estimated cost percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Down payment for project |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,900,000 | 239,000 |  | 239,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical trial cost for approval of food and drug administration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 23,500,000 | 13,200,000 |  |  |  |  |  |  |  |
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years ) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter ) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of Patients |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 24 |  |  |  |  |  |  |
Amount paid to each patient after Completing clinical trial |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16,000 |  | 31,366 |  |  | 500,000 |  | 34,383 | 38,501 |  |  |  | 31,771
Start-up fee for clinical trial |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 19,749 |  |  |  | 33,946 |  |  | 22,847 |  |  |  | 16,000
Start-up due cost paid date |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Dec. 31, 2013 |  |  |  |  |  |  |
Non - refundable institutional fee |  |  |  |  |  |  | 562,790 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 14,500 |  |  |  |  |  |  |
Annual pharmacy fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,025 |  |  |  |
Amendment processing fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 500 |  |  |  |
Accrued expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16,000 |
Accrued fees paid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16,000 |  |
Research recorded fees | 3,773,438 | 778,232 | 8,236,343 | 2,373,200 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 | 75,000 |  |  |  |  |  |  | 100,000 |  |  |  | 16,000 |  |
Total project estimated to cost |  |  |  |  | 800,000 |  |  |  | 183,391 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs | 300,000 |  |  |  |  |  |  |  | 92,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Security deposit | $ 34,733 |  | $ 34,733 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Amendment processing fee. + References No definition available. + Details
Name: | atnm_AmendmentProcessingFee
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount to be paid for each Patient that has completed the clinical trial. + References No definition available. + Details
Name: | atnm_AmountPaidToEachPatient
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Clinical trial cost for approval of food and drug administration. + References No definition available. + Details
Name: | atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | atnm_CommitmentsAndContingenciesTextualAbstract
Namespace Prefix: | atnm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of royalty payment to related party. + References No definition available. + Details
Name: | atnm_DescriptionOfRoyaltyPaymentToRelatedParty
Namespace Prefix: | atnm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Down payment for project. + References No definition available. + Details
Name: | atnm_DownPaymentForProject
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of total estimated project cost required for down payment. + References No definition available. + Details
Name: | atnm_DownPaymentOfProjectEstimatedCostPercentage
Namespace Prefix: | atnm_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition First commercial sale period. + References No definition available. + Details
Name: | atnm_FirstCommercialSalePeriod
Namespace Prefix: | atnm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fund to related party under agreement after year two. + References No definition available. + Details
Name: | atnm_FundToRelatedPartyUnderAgreementAfterYearTwo
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fund to related party under agreement for first two Year. + References No definition available. + Details
Name: | atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Long term purchase commitment milestones payment. + References No definition available. + Details
Name: | atnm_LongTermPurchaseCommitmentMilestonesPayment
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non refundable institutional fee. + References No definition available. + Details
Name: | atnm_NonRefundableInstitutionalFee
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of patients. + References No definition available. + Details
Name: | atnm_NumberOfPatients
Namespace Prefix: | atnm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition License fee payment. + References No definition available. + Details
Name: | atnm_PaymentOfLicenseFee
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Pharmacy fee. + References No definition available. + Details
Name: | atnm_PharmacyFee
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Project estimated cost. + References No definition available. + Details
Name: | atnm_ProjectEstimatedCost
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchase of radioactive material. + References No definition available. + Details
Name: | atnm_PurchaseOfRadioactiveMaterial
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty of net sales percentage. + References No definition available. + Details
Name: | atnm_RoyaltyOfNetSalesPercentage
Namespace Prefix: | atnm_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Start-up due cost paid date. + References No definition available. + Details
Name: | atnm_StartUpDueCostPaidDate
Namespace Prefix: | atnm_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Start-up fee for clinical trial. + References No definition available. + Details
Name: | atnm_StartUpFeeForClinicalTrial
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.15(a)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph a -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph 5 -Article 9 + Details
Name: | us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The current amount of expenditures for a real estate project that has not yet been completed. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.10) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 + Details
Name: | us-gaap_DevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LegalFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8,17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_SecurityDeposit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant